Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2008-07-22
2008-07-22
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S192100, C424S234100, C424S184100, C530S300000, C530S328000, C530S350000, C530S825000, C514S002600
Reexamination Certificate
active
10780106
ABSTRACT:
The present invention provides methods for eliciting an immune response against Group Astreptococci, comprising use of recombinant fusion polypeptides, and compositions thereof, that include a multivalent immunogenic portion of at least two immunogenic polypeptides from Group AstreptococciM proteins (which are capable of stimulating a protective immune response against Group Astreptococci), and a reiterated polypeptide from the immunogenic portion carboxy-terminal to the immunogenic portion, wherein the carboxy-terminal polypeptide is not required to stimulate an immune response against Group Astreptococci.
REFERENCES:
patent: 4284537 (1981-08-01), Beachey
patent: 4454121 (1984-06-01), Beachey
patent: 4521334 (1985-06-01), Beachey
patent: 4597967 (1986-07-01), Beachey
patent: 4705684 (1987-11-01), Beachey
patent: 4784948 (1988-11-01), Scott et al.
patent: 4919930 (1990-04-01), Beachey et al.
patent: 5124153 (1992-06-01), Beachey et al.
patent: 5334379 (1994-08-01), Pillai et al.
patent: 5985654 (1999-11-01), Fischetti et al.
patent: 6063386 (2000-05-01), Dale et al.
patent: 6419932 (2002-07-01), Dale
patent: 6716433 (2004-04-01), Dale
patent: 7063850 (2006-06-01), Dale
patent: 7074416 (2006-07-01), Dale
patent: 7255863 (2007-08-01), Dale
patent: 7270827 (2007-09-01), Reddish et al.
patent: 2006/0246083 (2006-11-01), Dale
patent: 2007/0053937 (2007-03-01), Dale
patent: WO 94/06421 (1994-03-01), None
patent: WO 94/06465 (1994-03-01), None
patent: WO 00/37648 (2000-06-01), None
Ada,Fundamental Immunology, William E. Paul, M.D. (ed.), 2ndEdition, Raven Press, New York, 1989, pp. 1010-1011.
Baird et al., “Epitopes Of Group A Streptococcal M Protein Shared With Antigens Of Articular Cartilage And Synovim,”The Journal Of Immunology 146(9):3132-3137, 1991.
Beachey and Ofek, “Epithelial Cell Binding Of Group AStreptococciBy Lipoteichoic Acid On Fimbriae Denuded Of M Protein,”The Journal Of Experimental Medicine 143:759-771. 1976.
Beachey and Seyer, “Protective And Nonprotective Epitopes Of Chemically Synthesized Peptides Of The NH2-Terminal Region Of Type 6 Streptococcal M Protein,”The Journal Of Immunology 136(6):2287-2292, 1986.
Beachey and Seyer,Seminars in Infectious Disease. vol. IV Bacterial Vaccines, Thieme-Stratton Inc., New York, New York, 1982, Chapter Fifty-Seven, “Primary Structure And Immuno-Chemistry Of Group A Streptococcal M Proteins,” pp. 401-410.
Beachey and Stollerman, “Mediation of Cytotoxic Effects of Streptococcal M Protein by Nontype-Specific Antibody in Human Sera,”The Journal of Clinical Investigation 52:2563-2570, 1973.
Beachey and Stollerman, “Toxic Effects Of Steptococcal M Protein On Platelets And Polymorphonuclear Leukocytes In Human Blood,”The Journal Of Experimental Medicine 134:351-365, 1971.
Beachey et al., “Human Immune Response To Immunization With a Structurally Defined Polypeptide Fragment Of Streptococcal M Protein,”J. Exp. Med. 150:862-877, 1979.
Beachey et al., “Immunogenicity In Animals And Man Of A Structurally Defined Polypeptide Of Streptococcal M Protein,”Transactions Of The Association Of American Physicians, vol. XCII:pp. 346-354, 1979.
Beachey et al., “Opsonic Antibodies Evoked By Hybrid Peptide Copies Of Types 5 and 24 Streptococcal M Proteins Synthesized In Tandem,”J. Exp. Med.163: 1451-1458, 1986.
Beachey et al., “Peptic Digestion of Streptococcal M Protein. II. Extraction of M Antigen from Group A Streptococci With Pepsin,”Infection And Immunity 9(5):891-896, 1974.
Beachey et al., “Primary Structure of Protective Antigens of Type 24 Streptococcal M Protein,”The Journal Of Biological Chemistry 255(13):6284-6289, 1980.
Beachey et al., “Protective Immunogenicity And T Lymphocyte Specificity Of A Trivalent Hybrid Peptide Containing NH2-Terminal Sequences Of Types, 5, 6, and 24 M Proteins Synthesized In Tandem,”The Journal Of Experimental Medicine 166:647-656, 1987.
Beachey et al., “Purification And Properties Of M Protein Extracted From Group A Streptococci With Pepsin: Covalent Structure Of The Amino Terminal Region Of Type 24 M Antigen,”The Journal Of Experimental Medicine 145:1469-1483, 1977.
Beachey et al., “Repeating Covalent Structure and Protective Immunogenicity of Native and Synthetic Polypeptide Fragments of Type 24 Steptococcal M Protein,”The Journal Of Biological Chemistry 258(21):13250-13257, 1983.
Beachey et al., “Repeating covalent structure of streptococcal M protein,”Proc. Natl. Acad. Sci. USA 75(7):3163-3167, 1978.
Beachey et al., “Separation Of The Type Specific M Protein From Toxic Cross Reactive Antigens Of Group A Streptococci,”Transactions Of The Association Of American Physicians. Ninetieth Session vol. XC: 390-400, 1977.
Beachey et al., “Type-specific protective immunity evoked by synthetic peptide ofStreptococcus pyogenesM Protein,”Nature(London) 292:457-459, 1981.
Beall et al., “Sequencingemm-Specific PCR Products for Routine and Accurate Typing of Group A Streptococci,”Journal of Clinical Microbiology 34(4):953-958, Apr. 1996.
Blenden et al., “Growth ofListeria monocytogenesin a Corn Silage Extract Medium,”American Journal Of Veterinary Research 29(11):2237-2242, 1968.
Bricas et al., “Structure Et Synthese De La Subunite Peptide De La Paroi De Trois Bacteries, Gram-Postif,”Proceedings of the Eight European Peptide Symposium Sep. 1966, Noorkwijk, Neth., North-Hollad Publishing Company: Amsterdam, Neth. And Interscience Publishers Division, John Wiley and Sons, Inc., New York, 1967, 286-292 (+Biological Abstracts 50(4):Abstract No. 20361, 1936).
Bronze et al., “Protective And Heart-Cross Reactive Epitopes Located Within The NH2Terminus Of Type 19 Streptococcal M Protein,”The Journal Of Experimental Medicine 167:1849-1859, 1988.
Chou and Fasman, “Prediction of Protein Conformation,”Biochemistry 13(2):222-245, 1974.
Cunningham and Beachey, “Peptic Digestion of Streptococcal M Protein. I. Effect of Digestion at Suboptimal pH upon the Biological and Immunochemical Properties of Purified M Protein Extracts,”Infection And Immunity 9(2):244-248, 1974.
Cunningham et al., “Human And Murine Antibodies Cross-Reactive With Streptococcal M Protein And Myosin Recognize The Sequence Gln-Lys-Ser-Lys-Gln In M Protein,”The Journal Of Immunology 143(8):2677-2683, 1989.
Dale, “Group A Streptococcal Vaccines,”New Vaccines And New Vaccine Technology 13(1):227-243, 1999.
Dale, “Group A Streptococcal Vaccines,”Pediatric Annals 27:301-308, 1998.
Dale, “Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments,”Vaccine 17:193-200, 1999.
Dale and Beachey, “Multiple, Heart-Cross-Reactive Epitopes Of Streptococcal M Proteins,”Journal Of Experimental Medicine 161: 113-122, Jan. 1985.
Dale and Beachey, “Epitopes Of Streptococcal M Proteins Shared With Cardiac Myosin,”The Journal Of Experimental Medicine 162:583-591, 1985.
Dale and Beachey, “Localization Of Protective Epitopes Of The Amino Terminus Of Type 5 Streptococcal M Protein,”The Journal Of Experimental Medicine 163:1191-1202, 1986.
Dale and Beachey, “Sequence Of Myosin-Crossreactive Epitopes Of Streptococcal M Protein,”Journal Of Experimental Medicine 164:1785-1790, 1986.
Dale et al., “Heterogeneity Of Type-Specific And Cross-Reactive Antigenic Determinants Within A Single M Protein Of Group A Streptococci,”The Journal Of Experimental Medicine 151:1026-1038, 1980.
Dale et al., “Blastogenic Reponses Of Human Lymphocytes To Structurally Defined Polypeptide Fragments Of Streptococcal M Protein,”The Journal Of Immunology 126(4):1499-1505, 1981.
Dale et al., “Type-Specific Immunogenicity Of A Chemically Synthesized Peptide Fragment Of Type 5 Streptococcal M Protein,”
Devi S.
Seed IP Law Group PLLC
University of Tennessee Research Foundation
LandOfFree
Group A streptococcal vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Group A streptococcal vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Group A streptococcal vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3921909